Letter to the Editor: Waning Vaccine Immunity and the Need for a Third (Booster) Vaccine to Prevent Breakthrough Infections against COVID-19

Cameron Y. S. Lee^{1, 2,} and Jon B. Suzuki³

¹Oral, Maxillofacial and Reconstructive Surgery, Aiea, Hawaii 96701

²Department of Periodontology/Oral Implantology, Kornberg School of Dentistry, Temple University, Philadelphia, PA 19140

³Departments of Periodontology/Oral Implantology and Microbiology/Immunology, Temple University School of Dentistry and Medicine, Temple University, Philadelphia, PA 19140

Cite this paper:
Cameron Y. S. Lee and Jon B. Suzuki. Letter to the Editor: Waning Vaccine Immunity and the Need for a Third (Booster) Vaccine to Prevent Breakthrough Infections against COVID-19. American Journal of Public Health Research. 2022; 10(1):1-2. doi: 10.12691/ajphr-10-1-1

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Tegally H, Wilkinson E, Giovanetti M, et al. Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein.
[2]	Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403-416.
[3]	Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603-2615.
[4]	Thomas SJ, Moreira ED Jr, Kitchin N, et al. Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. July 28, 2021 (http://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1).
[5]	Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. Published online October 6, 2021.
[6]	Israel A, Merzon E, Schaffer AA, et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. August 5, 2021 (https://www.medrxiv.org/content/10.1101/2021.08.03.21261496v1.
[7]	Centers for Disease Control and Prevention a. Outbreak of SARS-CoV-2 infections, including Covid-19 vaccine breakthrough infections, associated with large public gatherings. Barnstable County, Massachusetts, July 2021. www.cdc.gov/mmwr/volumes/70/wr/mm7031e2.htm. Accessed 11/14/2021.
[8]	Falsey AR, Frenck RW, Kitchin N, et al. SARS-CoV-2 neutralization with BNT1622b vaccine dose. New Engl J Med 2021; 385: 1627-1629.
[9]	Khoury DS, Cromer D. Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205-1211.
[10]	Cromer D, Juno JA, Khoury, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol 2021; 12(6); 395-404.
[11]	Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2in mild-moderate COVID-19. Nat Common 2021; 12(1): 1162.
[12]	Zollner A, Watschinger C, Rossler C, et al. B and T cell response to SARS-CoV-2 vaccination I health care professionals with and without previous COVID-19. Ebio Medicine 2021; 70: 103539.
[13]	Eliakim-Raz N, Massarweh A, Stemmer A, et al. Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment. JAMA Oncol. Published online August 11, 2021.